MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $38.63M | $41.29M | $44.26M | $33.89M | $26.17M | $21.62M | $16.67M | $13.98M |
| Cost of Revenue | $7.10M | $4.74M | $5.10M | $3.65M | $2.77M | $2.50M | $1.84M | $1.45M |
| Gross Profit | $31.53M | $36.55M | $39.16M | $30.25M | $23.40M | $19.12M | $14.83M | $12.53M |
| Gross Margin | 81.62% | 88.51% | 88.48% | 89.24% | 89.43% | 88.44% | 88.96% | 89.61% |
| Operating Expenses | $82.72M | $84.84M | $66.52M | $48.44M | $34.46M | $31.54M | $23.25M | $21.82M |
| Operating Income | $-51.20M | $-48.30M | $-27.36M | $-18.19M | $-11.06M | $-12.42M | $-8.42M | $-9.29M |
| Operating Margin | -132.54% | -116.98% | -61.82% | -53.66% | -42.25% | -57.44% | -50.55% | -66.44% |
| Net Income | $-41.05M | $-37.92M | $-23.57M | $-19.08M | $-11.82M | $-12.89M | $-8.87M | $-9.92M |
| Net Margin | -106.29% | -91.85% | -53.25% | -56.30% | -45.15% | -59.64% | -53.21% | -70.91% |
| EPS (Basic) | $-0.39 | $-0.37 | $-0.19 | $-0.22 | $-0.18 | $-0.24 | $-0.17 | $-0.20 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |